Twice-daily bictegravir during rifampicin-based tuberculosis therapy: A pragmatic alternative.

Sánchez-Cano JG, Muñoz-Echeverría L, Casco-García M, Moreno-Núñez L

Open source

DOI
10.1111/hiv.70245
Published
2026 Aug
Container
HIV medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/hiv.70245,
  title = {Twice-daily bictegravir during rifampicin-based tuberculosis therapy: A pragmatic alternative.},
  author = {Sánchez-Cano JG and Muñoz-Echeverría L and Casco-García M and Moreno-Núñez L},
  year = {2026},
  journal = {HIV medicine},
  doi = {10.1111/hiv.70245},
  url = {https://doi.org/10.1111/hiv.70245}
}

RIS

TY  - JOUR
TI  - Twice-daily bictegravir during rifampicin-based tuberculosis therapy: A pragmatic alternative.
AU  - Sánchez-Cano JG
AU  - Muñoz-Echeverría L
AU  - Casco-García M
AU  - Moreno-Núñez L
PY  - 2026
JO  - HIV medicine
DO  - 10.1111/hiv.70245
UR  - https://doi.org/10.1111/hiv.70245
ER  - 

APA

JG, S., L, M., M, C., & L, M. (2026). Twice-daily bictegravir during rifampicin-based tuberculosis therapy: A pragmatic alternative.. HIV medicine. https://doi.org/10.1111/hiv.70245

Source records